As associate director of basic research, Lori Hazlehurst, PhD, oversees a laboratory that is focused on translational research with an overall goal of developing novel therapeutic strategies for the treatment of cancer. She fosters transdisciplinary teams to guide innovative strategies for the pre-clinical validation of innovative approaches for diagnosis and treatment of cancer patients.
Dr. Hazlehurst is developing strategies for targeting the tumor microenvironment to increase the efficacy of standard of care agents. Her current research focus is to develop strategies for targeting Ca2+ homeostasis and protein folding in cancer.
Dr. Hazlehurst earned her PhD from the Cell and Molecular Biology Program at the University of Vermont. Her post-doctoral studies were performed at the University of Arizona and the Moffitt Cancer Center in Tampa, Florida.
Hannah Hazard-Jenkins, MD
Director, WVU Cancer Institute; Director and Associate Chair of Surgery for Cancer Services, WVU Cancer Institute
Nathan Burt, MHA
Interim Vice President, WVU Cancer Institute; Vice President of Operations, J.W. Ruby Memorial Hospital
Deborah Falconi, MSN, RN, OCN
Assistant Vice President, Cancer Services Operation and Strategy, WVU Cancer Institute
Michael Ridinger, MBA, RN, BSN
Associate Director, WVU Cancer Institute; Administrator, WVU Section of Hematology/Oncology